adriamycin...... 30 mg/sqm IV day 1 and 28.
vinblastine..... 6 mg/sqm IV day 1 and 18.
mitomycin....... 10 mg/sqm IV day 1.
FREQUENCY....... Repeat cycle every 8 weeks.
Luikart SD. Witman GB. Portlock CS. Adriamycin
(doxorubicin), vinblastine, and mitomycin C combination
chemotherapy in refractory breast carcinoma. Cancer.
54(7):1252-5, 1984 Oct 1.
Twenty-seven evaluable patients with refractory, metastatic
breast carcinoma were treated with Adriamycin (doxorubicin) 30
mg/m2 and vinblastine 6 mg/m2 intravenously on days 1 and 28
every 8 weeks, and mitomycin C 10 mg/m2 intravenously on day 1
every 8 weeks (AVM). There were three complete and six partial
responses for a total response rate of 33%. In addition, 2
patients had minimal responses, and 10 patients achieved
disease stabilization. Median time to disease progression for
responders was 116 days (range, 49-812+ days). Drug toxicity
was tolerable: 12 patients (44%) experienced significant bone
marrow suppression. There were no drug-related deaths.
Although AVM appears to be an active drug combination in
heavily pretreated patients with metastatic breast carcinoma,
the contribution of vinblastine and mitomycin C to single
agent Adriamycin in previously treated patients is not clear
from this study.